1. Oviva provides digitally-enhanced diabetes care and treatment through mobile applications and online resources. It has seen revolutionary results including 51% remission from prediabetes and 55% remission from type 2 diabetes. 2. Current diabetes treatments have issues with accessibility, scalability, and efficacy. Oviva's digital therapy removes barriers to access and can engage patients long-term at a lower cost than traditional face-to-face care. It has the largest real-world data on diabetes treatment in Europe. 3. Oviva is uniquely positioned to launch its "digital therapist" program due to its established access and reimbursement, profitable business model, engagement of most patients in major programs,

1. 1
Digitizing
Diabetes Care
NOAH Berlin
June 2019
© Oviva 2014-2019
Kai Eberhardt
CEO & Cofounder

2.  @NOAHConference
 @noah_conference
 @noah-conference
 @NOAHConference
FOLLOW USONSOCIAL

3. 2
with
pre-diabetes
150m
60m have Type 2
Diabetes in Europe
Source: WHO, European Journal of Public Health 2016
Eye
disease
Kidn
ey
disease
Diab
etic
footulcer
Diabetes Type 2 is an
epidemic
$200bDiabetes costs
Europe annually
+

4. 3
Current treatments are insufficient
Accessibility &
scalability
Efficacy
Pharma
Bariatric
surgery
Dietetic
care
Digital
therapy
High access barriers
& patient risk
Only manage symptoms,
not underlying issues
Repeated f2f meetings restrict access
& insufficient therapists to deliver care
$160b can be saved in Europe with today‘s treatment, if it reached the patient

5. 4
Integrated with doctors who diagnose the disease
(e.g. prediabetes) and then refer the patient to Oviva
Available remotely and asynchronously to the patient,
removing barriers of travel and appointment times
Supporting life-long active follow-up with technology
+
+
+
Antonio Murta
Co-initiator of P5 Health
Intervention Program, Portugal
«The system needs to change from ”patient drop-in”
to active engagement of at-risk populations»
Oviva digitally-enhances diabetes care …

6. 5
Source: NHS England Diabetes Prevention Programme 2019; Oviva Diabetes Prevent, N=1‘400
* Randomised control study Oviva
** Weight loss Diabetes Prevention Programme Oviva compared to face-to-face (intention to treat)
Patient engagement Outcomes
… with revolutionary results …
Patients
remaining
Patients
lost
22% 27% 80%
100 88
82
20
0%
Diagnosis Uptake Complete Follow-up
51% remission
from Prediabetes!
55% remission
from Diabetes Type 2*!
+70% patient Net
Promotor Score!
+68% more weight loss
vs. face-to-face therapy**!

7. 6
… and market-leadership in Europe
1st prize 2018 conference “Model of good care”
Swiss Ministry of Health
1st prize 2018 conference
Recognition
75‘000 DE, UK, FR, CH
$6m
4 9‘000
patients
treated to date in
revenue
run-rate
peer-reviewed
publications over
referring
doctors

8. 7
NHS Diabetes Prevention Programme (DPP) targeting 200‘000 patients
France & Portugal each launching a 10‘000 patient DPP program
UK initiating digital remission therapy for Diabetes Type 2
A new law announced in Germany for easier access to reimbursement for digital
In the US, over 400’000 patients are treated digitally for diabetes annually,
doubling year-on-year. This is just the beginning, with:
Care is transforming to digital
Jens Spahn
German Health Minister
«There should be reimbursement for apps
such as diaries for diabetes.»

9. 8
Has the power to engage long-term, really
retaining patients
Developed and optimized with a large
database of real world data
Delivers great clinical outcomes
+
+
+
We are building the
digital therapist
… digital and scalable

10. 9
2019E
Patients
cumulative
0.3k
2.8k
16k
50k
100k+
2015 2016 2017 2018
... with structured data on
- Physiological data (bloods, weight, activity)
- Medical diagnosis & history
- Objectives, patient goals and their achievement
- Engagement (app, learning materials, logging)
- Diet change (food images)
… the largest real-world data collection in Europe
Oviva is uniquely positioned to launch the digital therapist with …

11. 10
Channel
Reimbursement
Clinical guidelines
Recurring referrals from doctors with a scalable approach.
Via existing codes and budgets.
Included in medical guidelines as first-line and repeated
therapy along treatment pathways.
There are 1’000s of consumer apps.
We are working within the established medical guidelines and regulatory framework and paid for today.
Oviva is uniquely positioned to launch the digital therapist with …
… established access & reimbursement

12. 11
-1
0
1
2
3
Patient CLV/CAC
Profitability
2016 2017 2018 2019E
Oviva is uniquely positioned to launch the digital therapist with …
… profitable unit economics

13. 12
0%
15%
15%
15%
55%
Oviva captured 55% of patients of the NHS Diabetes Prevention Programme
due to our execution, outcomes and our clinically-driven approach.
... most patients in the largest program in the world
Oviva is uniquely positioned to launch the digital therapist with …
The tender faced off our
competitors in direct
comparison

14. 13
Kai
CEO
—
Fastest PhD ever @ ETH Zurich
Harvard Medical School
McKinsey Junior Partner
Manuel
CTO
—
Msc Engineering @ ETH Zurich
Accenture Top Performer
Mark
Medical & UK
—
MD @ Imperial & Kings College
BCG & NHS Guy‘s & St. Thomas Trust
Lucy
Clinical & Product
—
Dietitian, Researcher,
TV Personality & Influencer
Carmen
Medical & CH
—
Msc Engineering @ ETH Zurich
& MD @ Uni Zürich
BCG & Roche Digital Ventures
Oviva is uniquely positioned to launch the digital therapist with …
… world-class leadership

15. 14
Starting fundraise
September 2019
kai@oviva.com

16. 15
Thank you!

17. 16
«Nothing I tried before
worked. As soon as I
started changing my diet,
my weight was dropping
fast! The biggest change
has been the mental– I
am more positive and
confident now. My
biggest problem is that
now none of my old
clothes fit!»
Andy, UK
-30kg
«In 3 years, all patients
will be treated the Oviva-
way.»
Prof. Dr. Marc Donath
Head of Endocrinology,
University Hospital Basel
«You saved my life. I
can’t believe what I used
to eat before. Now, after
losing 20kg, I am eligible
for weight loss surgery,
but may not go as I have
more confidence in
myself now. Thank you.»
Tim, UK
-20kg
«Very impressed, delivers
in a very friendly
informative way. Easy to
use. Yes, love it. 🤔
Thank you. 😀 »
Android app user
Playstore review

18. 17
To provide the best diet and lifestyle therapy through
technology.
To help 50 million people lead healthier and happier lives by 2025.
We place the patient first.
We begin with evidence, then measure and improve.
We tackle it together.
VISION
MISSION
VALUES
Who we are

19. 18
Simon Cartmell
BoD Chairman
—
Chairman of IESO; BoD member of 3
listed companies; prior CEO of ApaTech,
exited for $350m; VC experience
Graham Rich
Senior Advisor UK
—
Former CEO of a NHS payor region (Hull
PCT) and University Hospitals Bristol;
Chairman/BoD member of several health
technology companies
Pierre Moustial
BoD Member
—
CEO of Urgo, a leading woundcare company
(€700m revenues); sold past business for
>€1bn; Chairman medical technology
company association France
Prof. Hans Hauner
Medical Advisor
—
Thought leader for nutrition, obesity &
diabetes in Germany; co-author of
multiple national treatment guidelines
Prof. Tom Barber
Medical Advisor
—
Consultant Endocrinologist specializing in
Diabetes and Obesity;
Lead for the Human Metabolism Research
Unit at the University of Warwick
Eberhard Mehl
Senior Adivisor DE
—
Prior CEO German Society of General
Practitioners (GPs)
Board, advisors & investors

20. 19
Our Technology

21. 20
4 2.2 51%
3.5 11 26%
Our real world outcomes are
transformative
Weight loss
(kg)
HbA1c
reduction
(mmol/mol)
Reversal of
condition (%)Description
Oviva Way to
Wellness
Obesity
Oviva Diabetes
Prevent
Prediabetes
Oviva Diabetes
Support
Type 2 Diabetes
A 2 month intervention
combining dietitian & app for
type 2 diabetes education
A 9 month intervention
combining dietitian & app
for prediabetes
A 12 month behaviour change
intervention combining
dietitian, psychologist & app
6.5 N/A N/A

22. 21
Type 2 Diabetes
Remission
Study
8.9 9.5 55%
Weight loss
(kg)
HbA1c
reduction
(mmol/mol)
Reversal of
condition (%)
Swiss Obesity
Study
4.9 N/A N/A
Lion Study Expected 2020
Our clinical trials will further enhance
market leadership
RCT comparing long-term
weight loss maintenance of
Oviva app-based care vs.
pamphlets
Single-arm weight-loss with
pure Oviva app-based
support in obesity
RCT comparing continuous
vs. intermittent very low
energy diets, with Oviva app
support, for remission
Description

23. 22
E66
Patient Doctor Insurer
1 2 3
Bill insurers, on
established reimbursed
codes, with doctors referral
Revenues are recurring through annual patient re-referral (as per medical guidelines).
Revenue: $265 / referral
referral
Insurer reimbursement tied to delivering therapy and outcomes, not therapist time,
allowing Oviva to increase margins by replacing therapist time with technology
Revenue model

24. 23
We are the digital market leader
in Europe
Reimbursement
(Market access)
Distribution
(Patient access)
Face-to-face
community care
Oviva significantly outper-
formed in NHS DPP bids

25. 24
$250m
$500m
$1bn+ IPO
(estimated)
$29m
2017 Series A
Valuation